GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Rating of “Moderate Buy” by Brokerages

GeneDx Holdings Corp. (NASDAQ:WGS) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $78.14.

A number of brokerages have recently commented on WGS. The Goldman Sachs Group lifted their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. TD Securities cut their price target on GeneDx from $135.00 to $110.00 and set a “buy” rating for the company in a report on Thursday, May 1st. Finally, Wells Fargo & Company lowered their price objective on GeneDx from $105.00 to $78.00 and set an “equal weight” rating for the company in a research report on Thursday, May 1st.

GeneDx Trading Down 1.6 %

Shares of GeneDx stock opened at $56.44 on Friday. The business has a 50 day moving average price of $91.22 and a 200 day moving average price of $82.62. The company has a market capitalization of $1.58 billion, a P/E ratio of -28.79 and a beta of 1.96. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx has a 1 year low of $19.04 and a 1 year high of $117.75.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.17. The business had revenue of $87.12 million for the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Sell-side analysts anticipate that GeneDx will post 0.97 EPS for the current fiscal year.

Insider Transactions at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 46,594 shares of GeneDx stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $89.62, for a total transaction of $4,175,754.28. Following the transaction, the chief executive officer now directly owns 1,720 shares of the company’s stock, valued at $154,146.40. The trade was a 96.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 388 shares of the stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total transaction of $43,878.92. Following the completion of the sale, the chief financial officer now directly owns 3,337 shares of the company’s stock, valued at $377,381.33. The trade was a 10.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 139,390 shares of company stock worth $13,043,288 in the last ninety days. Insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On GeneDx

A number of large investors have recently modified their holdings of the stock. MCF Advisors LLC grew its position in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. Sterling Capital Management LLC increased its stake in GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after buying an additional 316 shares during the period. Global Retirement Partners LLC purchased a new position in GeneDx in the fourth quarter valued at about $28,000. GAMMA Investing LLC grew its stake in GeneDx by 151.7% during the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock valued at $39,000 after purchasing an additional 264 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in GeneDx during the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.